Exchange: NASDAQ·Updated 08:01 AM EDT

GOSS News

News
all
press releases
Gossamer’s Billion-Dollar Drug Bet Funded with $150M War Chest to Target FDA Approval
Gossamer Bio (NASDAQ:GOSS) is putting serious money behind a high-stakes regulatory bet. The company announced a structured private placement that could deliver up to $250 million, including $150 million of committed capital, as Gossamer races toward a planned September 2026 FDA submission for seralutinib in pulmonary arterial hypertension (PAH). The structure is milestone-driven: roughly $25 million is expected at the initial closing, another $125 million becomes available if the FDA accepts the NDA in 2026, and warrants could provide up to another $100 million if seralutinib ultimately receives FDA approval.
24-7 Market News
More News
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Gossamer Bio, Inc. (Nasdaq: GOSS) (the Company or Gossamer), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease...
Business Wire
Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -100.00% and +171.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
Gossamer Bio, Inc. (Nasdaq: GOSS) (the Company or Gossamer), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease...
Business Wire
Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of -119.21% and -2.88%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of +13.48% and +23.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm PR Newswire NEW YORK, Aug. 10, 2026 NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether...
PR Newswire
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD) shares movedread more...
Benzinga
This Honeywell Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts upgraded Grupo Cibest, Lufax, Honeywell, and Gossamer Bio. JBS also received an upgrade. See what analysts think.read more...
Benzinga

Advertisement|Remove ads.